{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T14:54:44Z","timestamp":1754146484613,"version":"3.41.2"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,18]]},"DOI":"10.7759\/cureus.88214","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T09:46:01Z","timestamp":1752831961000},"source":"Crossref","is-referenced-by-count":0,"title":["A Unique Presentation of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Presenting as Foot Drop in B-cell Acute Lymphoblastic Leukemia: A Case Report"],"prefix":"10.7759","author":[{"given":"Adelyn","family":"D Souza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chinmay","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karthick  N","family":"Vijayaraghavan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi-An","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Correa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1179\/102453308X343374","article-title":"Central nervous system involvement in adult acute lymphoblastic leukemia","volume":"13","author":"Thomas X","year":"2008","unstructured":"Thomas X, Le QH. Central nervous system involvement in adult acute lymphoblastic leukemia. Hematology. 2008, 13:293-302. 10.1179\/102453308X343374","journal-title":"Hematology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-208699","article-title":"Central nervous system relapse in adults with acute lymphoblastic leukemia: identifying key risk factors and survival outcomes","volume":"142","author":"Rangel LC","year":"2023","unstructured":"Rangel LC, Mart\u00ednez MA, Sol\u00eds-Huerta F, et al.. Central nervous system relapse in adults with acute lymphoblastic leukemia: identifying key risk factors and survival outcomes. Blood. 2023, 142:612. 10.1182\/blood-2024-208699","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2009.07.005","article-title":"Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia","volume":"23","author":"Thomas DA","year":"2009","unstructured":"Thomas DA, O'Brien S, Kantarjian HM. Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia. Hematol Oncol Clin North Am. 2009, 23:949-71, v. 10.1016\/j.hoc.2009.07.005","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-134470","article-title":"Real-world effectiveness and safety of blinatumomab in adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in Europe: 3-year results in Philadelphia chromosome-negative patients and a subset of patients with late first relapse","volume":"136","author":"Thomas X","year":"2020","unstructured":"Thomas X, Rijneveld AW, Fracchiolla N, et al.. Real-world effectiveness and safety of blinatumomab in adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in Europe: 3-year results in Philadelphia chromosome-negative patients and a subset of patients with late first relapse. Blood. 2020, 136:38-9. 10.1182\/blood-2020-134470","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp MS","year":"2015","unstructured":"Topp MS, G\u00f6kbuget N, Stein AS, et al.. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015, 16:57-66. 10.1016\/S1470-2045(14)71170-2","journal-title":"Lancet Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006035","article-title":"Characterization of extramedullary disease in B-ALL and response to\u00a0CAR\u00a0T-cell therapy","volume":"6","author":"Holland EM","year":"2022","unstructured":"Holland EM, Yates B, Ling A, et al.. Characterization of extramedullary disease in B-ALL and response to\u00a0CAR\u00a0T-cell therapy. Blood Adv. 2022, 6:2167-82. 10.1182\/bloodadvances.2021006035","journal-title":"Blood Adv"},{"key":"ref7","unstructured":"BLINCYTO\u00ae. (2024). Accessed. May 27, 2025: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/125557s030lbl.pdf#page=43."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-025-03913-6","article-title":"Adverse events in the nervous system associated with blinatumomab: a real-world study","volume":"23","author":"Gao W","year":"2025","unstructured":"Gao W, Yu J, Sun Y, et al.. Adverse events in the nervous system associated with blinatumomab: a real-world study. BMC Med. 2025, 23:72. 10.1186\/s12916-025-03913-6","journal-title":"BMC Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.03.006","article-title":"Clinical presentation, risk factors, and outcomes of immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T cell therapy: a systematic review","volume":"28","author":"Grant SJ","year":"2022","unstructured":"Grant SJ, Grimshaw AA, Silberstein J, Murdaugh D, Wildes TM, Rosko AE, Giri S. Clinical presentation, risk factors, and outcomes of immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T cell therapy: a systematic review. Transplant Cell Ther. 2022, 28:294-302. 10.1016\/j.jtct.2022.03.006","journal-title":"Transplant Cell Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02829-9","article-title":"Toxicity and effectiveness of CD19 CAR T therapy in children with high-burden central nervous system refractory B-ALL","volume":"70","author":"Tan Y","year":"2021","unstructured":"Tan Y, Pan J, Deng B, et al.. Toxicity and effectiveness of CD19 CAR T therapy in children with high-burden central nervous system refractory B-ALL. Cancer Immunol Immunother. 2021, 70:1979-93. 10.1007\/s00262-020-02829-9","journal-title":"Cancer Immunol Immunother"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00238-6","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials","volume":"8","author":"Leahy AB","year":"2021","unstructured":"Leahy AB, Newman H, Li Y, et al.. CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials. Lancet Haematol. 2021, 8:e711-22. 10.1016\/S2352-3026(21)00238-6","journal-title":"Lancet Haematol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-022-06297-0","article-title":"Neurology of cancer immunotherapy","volume":"44","author":"De Grado A","year":"2023","unstructured":"De Grado A, Cencini F, Priori A. Neurology of cancer immunotherapy. Neurol Sci. 2023, 44:137-48. 10.1007\/s10072-022-06297-0","journal-title":"Neurol Sci"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00715-0","article-title":"Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee","volume":"26","author":"Graham CE","year":"2025","unstructured":"Graham CE, Velasco R, Alarcon Tomas A, et al.. Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee. Lancet Oncol. 2025, 26:e203-13. 10.1016\/S1470-2045(24)00715-0","journal-title":"Lancet Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25008","article-title":"Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapies","volume":"116","author":"Jabbour E","year":"2010","unstructured":"Jabbour E, Thomas D, Cortes J, Kantarjian HM, O'Brien S. Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapies. Cancer. 2010, 116:2290-300. 10.1002\/cncr.25008","journal-title":"Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1055\/s-0041-1730752","article-title":"Isolated CNS relapse in acute lymphoblastic leukemia (ALL): an experience from a tertiary care center","volume":"13","author":"Tevatia MS","year":"2021","unstructured":"Tevatia MS, Sharma I, Jadhav T, Somasundaram V, Sharma S. Isolated CNS relapse in acute lymphoblastic leukemia (ALL): an experience from a tertiary care center. J Lab Physicians. 2021, 13:134-8. 10.1055\/s-0041-1730752","journal-title":"J Lab Physicians"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier B","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, et al.. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002, 346:235-42. 10.1056\/NEJMoa011795","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70235-2","article-title":"CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group","volume":"12","author":"Pfreundschuh M","year":"2011","unstructured":"Pfreundschuh M, Kuhnt E, Tr\u00fcmper L, et al.. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011, 12:1013-22. 10.1016\/S1470-2045(11)70235-2","journal-title":"Lancet Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"Habermann TM","year":"2006","unstructured":"Habermann TM, Weller EA, Morrison VA, et al.. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006, 24:3121-7. 10.1200\/JCO.2005.05.1003","journal-title":"J Clin Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-187164","article-title":"Retrospective review of patients treated with intrathecal rituximab for primary and secondary CNS lymphoma and leukemia","volume":"142","author":"Feldman T","year":"2023","unstructured":"Feldman T, Pia AD, Lee G, et al.. Retrospective review of patients treated with intrathecal rituximab for primary and secondary CNS lymphoma and leukemia. Blood. 2023, 142:1773. 10.1182\/blood-2023-187164","journal-title":"Blood"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/357728-a-unique-presentation-of-immune-effector-cell-associated-neurotoxicity-syndrome-icans-presenting-as-foot-drop-in-b-cell-acute-lymphoblastic-leukemia-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T09:46:02Z","timestamp":1752831962000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/357728-a-unique-presentation-of-immune-effector-cell-associated-neurotoxicity-syndrome-icans-presenting-as-foot-drop-in-b-cell-acute-lymphoblastic-leukemia-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.88214","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,18]]}}}